Balchem (BCPC)
Market Price (2/4/2026): $170.64 | Market Cap: $5.5 BilSector: Materials | Industry: Specialty Chemicals
Balchem (BCPC)
Market Price (2/4/2026): $170.64Market Cap: $5.5 BilSector: MaterialsIndustry: Specialty Chemicals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% | Trading close to highsDist 52W High is -3.0% | Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x, P/EPrice/Earnings or Price/(Net Income) is 37x |
| Low stock price volatilityVol 12M is 23% | Weak multi-year price returns2Y Excs Rtn is -20%, 3Y Excs Rtn is -36% | Key risksBCPC key risks include [1] a premium valuation facing significant downside if growth disappoints amid recent slowing momentum and [2] margin pressure from sustained tariffs on key products like choline chloride. |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Advanced Materials. Themes include Nutritional Supplements, Functional Foods & Beverages, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Low stock price volatilityVol 12M is 23% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Advanced Materials. Themes include Nutritional Supplements, Functional Foods & Beverages, Show more. |
| Trading close to highsDist 52W High is -3.0% |
| Weak multi-year price returns2Y Excs Rtn is -20%, 3Y Excs Rtn is -36% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 27x, P/EPrice/Earnings or Price/(Net Income) is 37x |
| Key risksBCPC key risks include [1] a premium valuation facing significant downside if growth disappoints amid recent slowing momentum and [2] margin pressure from sustained tariffs on key products like choline chloride. |
Qualitative Assessment
AI Analysis | Feedback
Balchem (BCPC) stock has gained about 10% since 10/31/2025 because of the following key factors:
1. Strong Q3 2025 Earnings and Positive Future Outlook. Balchem reported record third-quarter 2025 consolidated revenue of $268 million, an 11.5% increase year-over-year, and adjusted net earnings of $1.35 per diluted share, up 19.5% year-over-year, exceeding revenue consensus estimates. This strong performance, announced on October 21, 2025, was coupled with positive industry expectations for Q4 2025, including anticipated quarterly earnings of $1.29 per share and revenues reaching $264.03 million. Forecasted earnings for 2025 were also projected to be well over $5 per share.
2. Dividend Increase and Shareholder Value Initiatives. On December 10, 2025, Balchem announced a 10.3% increase in its annual dividend, raising it to $0.96 per share. This action, alongside the announcement of a stock buyback program, demonstrated a commitment to returning value to shareholders and signaled financial stability.
Show more
1. Strong Q3 2025 Earnings and Positive Future Outlook. Balchem reported record third-quarter 2025 consolidated revenue of $268 million, an 11.5% increase year-over-year, and adjusted net earnings of $1.35 per diluted share, up 19.5% year-over-year, exceeding revenue consensus estimates. This strong performance, announced on October 21, 2025, was coupled with positive industry expectations for Q4 2025, including anticipated quarterly earnings of $1.29 per share and revenues reaching $264.03 million. Forecasted earnings for 2025 were also projected to be well over $5 per share.
2. Dividend Increase and Shareholder Value Initiatives. On December 10, 2025, Balchem announced a 10.3% increase in its annual dividend, raising it to $0.96 per share. This action, alongside the announcement of a stock buyback program, demonstrated a commitment to returning value to shareholders and signaled financial stability.
Show more
Stock Movement Drivers
Fundamental Drivers
The 11.4% change in BCPC stock from 10/31/2025 to 2/3/2026 was primarily driven by a 11.4% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 153.39 | 170.80 | 11.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,014 | 1,014 | 0.0% |
| Net Income Margin (%) | 14.7% | 14.7% | 0.0% |
| P/E Multiple | 33.2 | 36.9 | 11.4% |
| Shares Outstanding (Mil) | 32 | 32 | 0.0% |
| Cumulative Contribution | 11.4% |
Market Drivers
10/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| BCPC | 11.4% | |
| Market (SPY) | 1.1% | 31.1% |
| Sector (XLB) | 18.4% | 55.5% |
Fundamental Drivers
The 12.0% change in BCPC stock from 7/31/2025 to 2/3/2026 was primarily driven by a 6.9% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 152.47 | 170.80 | 12.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 986 | 1,014 | 2.8% |
| Net Income Margin (%) | 14.5% | 14.7% | 1.7% |
| P/E Multiple | 34.6 | 36.9 | 6.9% |
| Shares Outstanding (Mil) | 32 | 32 | 0.3% |
| Cumulative Contribution | 12.0% |
Market Drivers
7/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| BCPC | 12.0% | |
| Market (SPY) | 9.4% | 18.7% |
| Sector (XLB) | 16.1% | 45.4% |
Fundamental Drivers
The 6.8% change in BCPC stock from 1/31/2025 to 2/3/2026 was primarily driven by a 14.1% change in the company's Net Income Margin (%).| (LTM values as of) | 1312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 159.96 | 170.80 | 6.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 942 | 1,014 | 7.6% |
| Net Income Margin (%) | 12.9% | 14.7% | 14.1% |
| P/E Multiple | 42.6 | 36.9 | -13.3% |
| Shares Outstanding (Mil) | 32 | 32 | 0.3% |
| Cumulative Contribution | 6.8% |
Market Drivers
1/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| BCPC | 6.8% | |
| Market (SPY) | 15.6% | 45.4% |
| Sector (XLB) | 15.9% | 59.0% |
Fundamental Drivers
The 32.1% change in BCPC stock from 1/31/2023 to 2/3/2026 was primarily driven by a 24.8% change in the company's Net Income Margin (%).| (LTM values as of) | 1312023 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 129.25 | 170.80 | 32.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 923 | 1,014 | 9.8% |
| Net Income Margin (%) | 11.8% | 14.7% | 24.8% |
| P/E Multiple | 38.0 | 36.9 | -2.8% |
| Shares Outstanding (Mil) | 32 | 32 | -0.8% |
| Cumulative Contribution | 32.1% |
Market Drivers
1/31/2023 to 2/3/2026| Return | Correlation | |
|---|---|---|
| BCPC | 32.1% | |
| Market (SPY) | 75.9% | 48.9% |
| Sector (XLB) | 26.4% | 57.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BCPC Return | 47% | -27% | 22% | 10% | -6% | 12% | 52% |
| Peers Return | 27% | -20% | 6% | -11% | 20% | 8% | 25% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| BCPC Win Rate | 92% | 42% | 50% | 42% | 42% | 100% | |
| Peers Win Rate | 63% | 42% | 50% | 43% | 52% | 80% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| BCPC Max Drawdown | -7% | -33% | -6% | -8% | -14% | 0% | |
| Peers Max Drawdown | -6% | -37% | -21% | -21% | -27% | -1% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IFF, DD, ADM, ZTS, ELAN. See BCPC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/3/2026 (YTD)
How Low Can It Go
| Event | BCPC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -34.1% | -25.4% |
| % Gain to Breakeven | 51.8% | 34.1% |
| Time to Breakeven | 761 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -29.3% | -33.9% |
| % Gain to Breakeven | 41.5% | 51.3% |
| Time to Breakeven | 217 days | 148 days |
| 2018 Correction | ||
| % Loss | -37.1% | -19.8% |
| % Gain to Breakeven | 59.0% | 24.7% |
| Time to Breakeven | 743 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -35.9% | -56.8% |
| % Gain to Breakeven | 56.1% | 131.3% |
| Time to Breakeven | 242 days | 1,480 days |
Compare to IFF, DD, ADM, ZTS, ELAN
In The Past
Balchem's stock fell -34.1% during the 2022 Inflation Shock from a high on 11/22/2021. A -34.1% loss requires a 51.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Balchem (BCPC)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
AI Analysis | Feedback
Here are 1-3 brief analogies for Balchem (BCPC):
The 'Intel Inside' for advanced nutritional ingredients.
Like IFF (International Flavors & Fragrances) but for nutrition and health components.
A specialized 3M focused on nutritional solutions and performance ingredients.
AI Analysis | Feedback
- Human Nutrition Ingredients: Provides essential nutrients, such as chelated minerals and choline, for food, beverages, and dietary supplements.
- Microencapsulated Food Ingredients: Offers controlled-release encapsulated flavors, nutrients, and food acids for use in food processing and functional foods.
- Animal Nutrition Choline Products: Manufactures choline chloride and other choline compounds crucial for livestock and poultry health and performance.
- Animal Nutrition Specialty Nutrients: Supplies highly bioavailable chelated minerals and rumen-protected fat and amino acids for enhanced animal health and productivity.
- Specialty Industrial Solutions: Develops custom microencapsulation for industrial applications and provides ethylene oxide abatement technologies.
AI Analysis | Feedback
Balchem (BCPC) primarily sells its products to **other companies** (business-to-business or B2B model) rather than directly to individual consumers. Due to the proprietary nature of customer relationships in the specialty ingredients and industrial applications sectors, Balchem does not publicly disclose the names of its individual major customer companies. Instead, it serves a diverse range of companies across various industries globally. Based on its business segments, Balchem's primary categories of customer companies include: * **Food, Beverage, and Dietary Supplement Manufacturers:** These companies use Balchem's specialized nutritional ingredients (such as microencapsulated nutrients, choline compounds, and mineral amino acid chelates) in the formulation and production of their finished consumer products like functional foods, drinks, infant formulas, and various dietary supplements. * **Animal Feed Manufacturers, Integrators, and Pet Food Companies:** Customers in this category incorporate Balchem's animal nutrition and health products (e.g., choline chloride, feed additives, and specialized mineral ingredients) into feed for livestock, poultry, aquaculture, and into companion animal food products. * **Industrial and Specialty Manufacturers:** This segment serves companies in specific industrial markets. These customers include manufacturers requiring solutions for medical device sterilization, companies operating in the oil and gas industry, and those utilizing performance gases and other specialized chemical applications.AI Analysis | Feedback
null
AI Analysis | Feedback
The management team members for Balchem (BCPC) are as follows:
Ted Harris, Chairman, President and Chief Executive Officer
Ted Harris joined Balchem in May 2015 and has been leading the company as Chairman, President, and Chief Executive Officer since 2017. Prior to Balchem, he was the President of Performance Materials and Senior Vice President at Ashland Global Holdings Inc. Before his tenure at Ashland, Mr. Harris held various leadership roles at FMC Corporation, including General Manager of the Food Ingredients Division. He earned a Bachelor in Chemical Engineering from Lehigh University and a Master of Business Administration from Harvard Business School. Mr. Harris also serves as an independent director on the Board of Directors of Pentair plc.
Martin Bengtsson, Executive Vice President, CFO and General Manager, Animal Nutrition & Health
Martin Bengtsson has served as Balchem's Executive Vice President, Chief Financial Officer, and General Manager of Animal Nutrition & Health since 2019. Before joining Balchem, Mr. Bengtsson was the Vice President and Chief Financial Officer at Honeywell Inc. from April 2018 to January 2019. He also held the role of Vice President and Chief Financial Officer for the Advanced Materials unit of Honeywell International from August 2016 to April 2018 and served in various other accounting and finance positions at Honeywell. Earlier in his career, he worked as a Senior Auditor at Deloitte.
Hatsuki Miyata, Executive Vice President, Chief Legal Officer and Secretary
Hatsuki Miyata serves as Balchem's Executive Vice President, Chief Legal Officer, and Secretary.
Frederic Boned, Sr. Vice President & General Manager, Human Nutrition & Health
Frederic Boned holds the position of Senior Vice President and General Manager, Human Nutrition & Health at Balchem.
Martin Reid, Sr. Vice President and Chief Supply Chain Officer
Martin Reid is the Senior Vice President and Chief Supply Chain Officer at Balchem, a role he has held since 2022. Prior to this, he was a Vice President at Balchem from January 2021 to September 2022. Before joining Balchem, Mr. Reid served as the Chief Supply Chain Officer at Godiva Chocolate from May 2019 to December 2020, and as Vice President of Supply Chain – North America Manufacturing at The Estee Lauder Companies Inc.
AI Analysis | Feedback
Here are the key risks to Balchem's business:- Financial Performance and Valuation Risk: Balchem faces investor concerns regarding its revenue growth and profitability, which have contributed to scrutiny of its recent financial performance and a decline in share price. The company's valuation, with a P/E ratio significantly above the US Chemicals industry and peers, poses a "real downside valuation risk if growth disappoints." There has also been a recent share price slide and slowing momentum, causing investors to reassess future opportunities.
- Regulatory and Compliance Challenges: Balchem is navigating regulatory challenges, including addressing environmental concerns and ensuring compliance with regulatory standards, which has increased its operational costs and negatively impacted its bottom line. Additionally, sustained tariff pressures, particularly concerning choline chloride, could squeeze margins and affect the company's premium valuation. Global trade protectionism generally presents a constant risk to Balchem's supply chain and raises the cost of regulatory compliance.
- Supply Chain Disruptions and Raw Material Price Volatility: The company is exposed to risks associated with raw material price volatility and potential supply chain disruptions. Managing these factors is crucial for maintaining operational stability and profitability.
AI Analysis | Feedback
1. The accelerating global shift towards alternative protein sources (e.g., cellular agriculture, precision fermentation, and plant-based proteins) poses a long-term threat to Balchem's Animal Nutrition & Health segment. As these novel food production methods scale and gain market share, they could significantly reduce the demand for traditional livestock farming and, consequently, for the animal nutrition ingredients that Balchem supplies to that industry.
2. Increasing global regulatory scrutiny and the active development and adoption of alternative sterilization methods present a threat to Balchem's Specialty Products segment, specifically concerning its ethylene oxide (EtO) derivatives used in medical device sterilization. Heightened environmental and health concerns are driving regulators and industry players to seek alternatives to EtO, which could diminish demand for Balchem's related products.
AI Analysis | Feedback
Balchem (BCPC) operates in three main business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The addressable markets for their main products and services are as follows:
Human Nutrition & Health
-
Choline (e.g., VitaCholine) and Choline Chloride:
- The global choline market is projected to be USD 1.2 billion in 2025 and is expected to reach USD 2.1 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.0%.
- The global choline chloride market was valued at USD 546 million in 2023 and is estimated to grow at over 7.6% CAGR from 2024 to 2032.
- The U.S. choline chloride market size reached USD 131.9 million in 2023.
-
Chelated Minerals (e.g., Albion Minerals):
- The global chelated minerals supplements market was valued at $1.6 billion in 2024 and is forecasted to reach $3.1 billion by 2033, growing at a CAGR of 7.2%.
-
Microencapsulation Technology:
- The global microencapsulation technology market size is calculated at US$ 7.56 billion in 2024 and is projected to reach around US$ 16.43 billion by 2034, expanding at a CAGR of 8.07% between 2025 and 2034.
- North America dominated the microencapsulation technology market in 2024, with approximately 35% of the revenue.
Animal Nutrition & Health
-
Choline and Choline Chloride:
- (See above under Human Nutrition & Health for global and U.S. market sizes for choline/choline chloride, as Balchem is a global leader in choline production for both human and animal nutrition).
-
Chelated Minerals:
- The global chelated minerals market size reached $4.62 billion in 2024 and is expected to grow to $6.93 billion in 2029 at a CAGR of 8.8%.
- North America was the largest region in the chelated minerals market in 2024.
-
Microencapsulation Technology:
- (See above under Human Nutrition & Health for global market sizes for microencapsulation technology, as it serves various markets including animal nutrition).
-
Overall Animal Nutrition/Animal Feed Additives:
- The global animal nutrition market size was valued at USD 27.78 billion in 2024 and is expected to reach USD 45.98 billion by 2032, at a CAGR of 20.10% during the forecast period.
- The global animal feed additives market is estimated to have a value of approximately USD 37 billion to USD 54 billion in 2023/2024. It is also forecast to reach USD 59.88 billion by 2029, at a CAGR of 5.6%.
- The North American animal feed additives market size is estimated at USD 12.34 billion in 2024 and forecast to reach USD 16.12 billion by 2030, at a CAGR of 5.2%.
Specialty Products
-
Plant Nutrition (Metalosate® Chelated Minerals):
- (The market size for chelated minerals mentioned above under Animal Nutrition & Health is also relevant here, as Metalosate® chelated minerals are provided to the agricultural market worldwide).
-
Performance Gases (e.g., Ethylene Oxide):
- null
AI Analysis | Feedback
Balchem (BCPC) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and favorable market trends. The key drivers are:- Strong Growth in Human Nutrition & Health Segment: Balchem anticipates continued robust performance in its Human Nutrition & Health segment, propelled by ongoing "better-for-you" trends in the food and nutrition markets. The company's unique portfolio of minerals, nutrients, vitamins, and food ingredients and solutions aligns well with consumer demand for nutrient-dense, high-protein, high-fiber, and lower-sugar foods. This segment has consistently delivered record sales and earnings, with strong demand for its products.
- Expansion of Microencapsulation Capacity and New Product Launches: A significant driver of future revenue is Balchem's strategic investment in doubling the capacity of its microencapsulation manufacturing facility, expected by early 2027. This expansion is designed to support sustained double-digit growth in this high-margin product line. Additionally, the continuous launch of new innovative products, such as VitaCholine Pro-Flo and K2VITAL DELTA Fermented, across its segments, particularly in Human Nutrition & Health, is expected to enhance market penetration and drive sales.
- Increased Market Penetration of Specialty Nutrients and Delivery Systems: Balchem emphasizes the ongoing market penetration of its distinct portfolio of specialty nutrients and delivery systems as a core growth engine. This strategy involves expanding the reach of its scientifically backed solutions across various applications.
- Recovery and Strategic Penetration in Animal Nutrition & Health: Following some fluctuations, the Animal Nutrition & Health segment is expected to contribute to revenue growth through further market penetration of its rumen-protected precision release encapsulates nutrient portfolio. The company is also actively pursuing new initiatives targeting the companion animal sector and benefiting from improved European market conditions.
AI Analysis | Feedback
Share Repurchases
- Balchem has a stock repurchase program, initially authorized in June 1999, with a total authorization of 3,763,038 shares, of which 3,142,028 shares had been repurchased as of December 31, 2024.
- Total common stock repurchases for the nine months ended September 30, 2025, amounted to $54.0 million.
- In Q2 2025, the company repurchased $33.3 million in common stock.
Share Issuance
- Proceeds from stock options exercised totaled $6.867 million for the nine months ended September 30, 2025.
- Proceeds from stock options exercised totaled $15.084 million for the nine months ended September 30, 2024.
Outbound Investments
- On June 21, 2022, Balchem acquired Kappa Bioscience AS, a leading manufacturer of specialty vitamin K2 for the human nutrition industry.
- In 2023, Balchem acquired Bergstrom Nutrition, adding its OptiMSM® brand to strengthen the Human Nutrition and Health and Animal Nutrition and Health segments.
- The company reported significant cash paid for acquisitions, net of cash acquired, totaling $323 million for the nine months ended September 30, 2025.
Capital Expenditures
- Capital expenditures for the nine months ended September 30, 2025, were $27.275 million, compared to $22.936 million for the same period in 2024.
- Balchem projects capital expenditures for 2025 to range from $40 million to $45 million, with a focus on energy and water-saving projects and exploring renewable energy opportunities.
- The company announced plans for a new $36 million microencapsulation manufacturing facility in Orange County, NY, to more than double capacity for these technologies, with production expected to commence late 2027 into 2028.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Balchem Earnings Notes | 12/29/2026 | |
| How Low Can Balchem Stock Really Go? | 10/17/2025 | |
| Balchem vs Alphabet: Which Is A Better Investment? | 08/18/2025 | |
| Balchem vs Newmont: Which Is A Better Investment? | 08/18/2025 | |
| How Does Balchem Stock Stack Up Against Its Peers? | 08/13/2025 | |
| Better Bet Than BCPC Stock: Pay Less Than Balchem To Get More From GOOGL, METAÂ | 08/12/2025 | |
| Better Bet Than BCPC Stock: Pay Less Than Balchem To Get More From CRS, CDEÂ | 08/12/2025 | |
| BCPC Dip Buy Analysis | 07/10/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 10/10/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 68.88 |
| Mkt Cap | 18.5 |
| Rev LTM | 10,234 |
| Op Inc LTM | 1,199 |
| FCF LTM | 835 |
| FCF 3Y Avg | 614 |
| CFO LTM | 1,492 |
| CFO 3Y Avg | 1,534 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.9% |
| Rev Chg 3Y Avg | 0.9% |
| Rev Chg Q | 4.8% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | 11.9% |
| Op Mgn 3Y Avg | 10.8% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 14.5% |
| CFO/Rev 3Y Avg | 12.7% |
| FCF/Rev LTM | 8.7% |
| FCF/Rev 3Y Avg | 5.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 18.5 |
| P/S | 2.1 |
| P/EBIT | 21.1 |
| P/E | 23.9 |
| P/CFO | 18.9 |
| Total Yield | 1.8% |
| Dividend Yield | 1.5% |
| FCF Yield 3Y Avg | 2.9% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 9.5% |
| 3M Rtn | 12.7% |
| 6M Rtn | 14.1% |
| 12M Rtn | 23.1% |
| 3Y Rtn | 6.8% |
| 1M Excs Rtn | 8.6% |
| 3M Excs Rtn | 10.7% |
| 6M Excs Rtn | 8.7% |
| 12M Excs Rtn | 7.2% |
| 3Y Excs Rtn | -58.6% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $170.80 | |
| Market Cap ($ Bil) | 5.5 | |
| First Trading Date | 06/03/1986 | |
| Distance from 52W High | -3.0% | |
| 50 Days | 200 Days | |
| DMA Price | $158.96 | $157.94 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 7.5% | 8.1% |
| 3M | 1YR | |
| Volatility | 22.3% | 22.6% |
| Downside Capture | 8.42 | 46.40 |
| Upside Capture | 74.54 | 45.16 |
| Correlation (SPY) | 31.2% | 45.4% |
BCPC Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.23 | 0.85 | 0.60 | 0.36 | 0.53 | 0.75 |
| Up Beta | 1.97 | 1.51 | 0.83 | 1.09 | 0.60 | 0.77 |
| Down Beta | 2.39 | 1.52 | 0.96 | 0.00 | 0.54 | 0.64 |
| Up Capture | 118% | 76% | 67% | 37% | 33% | 49% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 9 | 17 | 25 | 53 | 115 | 369 |
| Down Capture | -124% | -21% | 9% | 20% | 55% | 94% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 24 | 36 | 72 | 135 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BCPC | |
|---|---|---|---|---|
| BCPC | 7.2% | 22.6% | 0.24 | - |
| Sector ETF (XLB) | 15.9% | 20.3% | 0.62 | 58.9% |
| Equity (SPY) | 15.6% | 19.2% | 0.63 | 45.4% |
| Gold (GLD) | 77.2% | 24.5% | 2.30 | 1.0% |
| Commodities (DBC) | 10.0% | 16.5% | 0.40 | 6.7% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | 54.2% |
| Bitcoin (BTCUSD) | -23.4% | 40.3% | -0.56 | 13.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BCPC | |
|---|---|---|---|---|
| BCPC | 9.5% | 24.4% | 0.36 | - |
| Sector ETF (XLB) | 9.5% | 18.9% | 0.40 | 58.6% |
| Equity (SPY) | 14.5% | 17.0% | 0.68 | 53.7% |
| Gold (GLD) | 21.5% | 16.8% | 1.04 | 7.6% |
| Commodities (DBC) | 12.0% | 18.9% | 0.51 | 8.1% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 55.1% |
| Bitcoin (BTCUSD) | 20.9% | 57.5% | 0.56 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BCPC | |
|---|---|---|---|---|
| BCPC | 12.6% | 27.4% | 0.47 | - |
| Sector ETF (XLB) | 12.5% | 20.7% | 0.54 | 55.6% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 54.4% |
| Gold (GLD) | 15.6% | 15.5% | 0.84 | 1.0% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 16.3% |
| Real Estate (VNQ) | 5.6% | 20.8% | 0.24 | 46.2% |
| Bitcoin (BTCUSD) | 69.9% | 66.5% | 1.09 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/21/2025 | 4.1% | 2.5% | 2.1% |
| 7/31/2025 | 0.2% | 5.2% | 6.5% |
| 2/21/2025 | 1.5% | 6.6% | -0.1% |
| 10/25/2024 | 3.2% | 0.7% | 9.8% |
| 7/26/2024 | 3.4% | 0.7% | -1.2% |
| 5/3/2024 | 2.8% | 6.0% | 5.8% |
| 2/16/2024 | 1.9% | 7.2% | 6.5% |
| 7/28/2023 | 1.8% | 4.2% | 7.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 14 | 15 |
| # Negative | 8 | 7 | 6 |
| Median Positive | 2.1% | 4.5% | 5.8% |
| Median Negative | -1.6% | -4.9% | -1.6% |
| Max Positive | 4.1% | 7.2% | 10.7% |
| Max Negative | -7.9% | -15.5% | -15.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 10/21/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/21/2025 | 10-K |
| 09/30/2024 | 10/25/2024 | 10-Q |
| 06/30/2024 | 07/26/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/16/2024 | 10-K |
| 09/30/2023 | 10/27/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 07/29/2022 | 10-Q |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fischer, David B | Direct | Sell | 12052025 | 153.97 | 8,000 | 1,231,748 | 1,230,055 | Form | |
| 2 | Van, Gunsteren Job Leonard | SVP and GM, Specialty Products | Direct | Sell | 12052025 | 153.29 | 6,000 | 919,723 | 1,447,950 | Form |
| 3 | Reid, Martin Luther | SVP Chief Supply Chain Officer | Direct | Sell | 11132025 | 154.44 | 1,200 | 185,328 | 1,141,466 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.